Work

Assessment of metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, and metabolic dysfunction and alcohol-associated steatotic liver disease in open Mexican population

Year: 2025

Type: article

Abstract: INTRODUCTION AND OBJECTIVES: The concept of Metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD) is recent. Patients with MetALD may have a higher risk of developing steatosis, inflammation, fibrosis, and cirrhosis than Metabolic dysfunction-associated steatotic liver disease (MASLD) or Alcohol-associated liver disease (ALD) patients. This study aims to evaluate the presence and grade of steatosis and liver fibrosis in the open Mexican population to determine the frequency and stage of MASLD, ALD, and MetALD. PATIENTS AND METHODS: Subjects aged 18 years or older, of any gender, and with a body mass index (BMI) of 18.5 or higher, who were healthy and without pre-existing chronic diseases, liver disease, or cancer, and who donated blood to our center's blood bank between June 1, 2021, and March 31, 2022, were included. To estimate the grade of steatosis and liver fibrosis, vibration-controlled transient elastography (VCTE) was performed. The subjects were classified according to VCTE and alcohol consumption pattern into one of four groups: healthy subjects (HS), ALD, MASLD, and MetALD. RESULTS: The prevalence of MASLD, ALD, and MetALD was 45.3%, 17.5%, and 5.8%, respectively. Only 31.4% were considered as HS. However, the average BMI was out of range in all four groups, including HS. Grade 3 steatosis was observed in the MASLD and MetALD groups. Liver stiffness showed higher values in the MetALD group. CONCLUSIONS: MetALD has the lowest prevalence compared to MASLD and ALD. However, MetALD has the highest grade of steatosis and liver fibrosis. High BMI and risky alcohol consumption were associated with the severity of liver disease.

Source: Annals of Hepatology

DOI: 10.1016/j.aohep.2025.102149